10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2021

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                        to                        

Commission File No. 000-27873

America Great Health

(Exact name of registrant as specified in its charter)

Wyoming (State or other jurisdiction of incorporation or organization)	98-0178621 (I.R.S. Employer Identification No.)
1609 W Valley Blvd Unit 338A Alhambra, CA (Address of principal executive offices)	91803 (Zip Code)

(626) 576-1299

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐   No ☒

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐
Non-accelerated filer ☐	Smaller reporting company ☒
Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐   No ☒

Indicate the number of shares outstanding of each of the registrant’s classes of common stock, as of the latest practicable date. The number of shares outstanding of the registrant’s common stock as of Ju1y 11, 2021 was 21,070,866,399.

AMERICA GREAT HEALTH AND SUBSIDIARIES

TABLE OF CONTENTS

PART I – FINANCIAL INFORMATION		3
ITEM 1	Condensed Consolidated Financial Statements (Unaudited)	3
ITEM 2	Management’s Discussion and Analysis of Financial Condition and Results of Operations	14
ITEM 3	Quantitative and Qualitative Disclosures About Market Risk	18
ITEM 4	Controls and Procedures	18
PART II – OTHER INFORMATION		19
ITEM 1	Legal Proceedings	19
ITEM 1A	Risk Factors	19
ITEM 2	Unregistered Sales of Equity Securities and Use of Proceeds	19
ITEM 3	Defaults Upon Senior Securities	19
ITEM 4	Mine Safety Disclosures	19
ITEM 5	Other Information	19
ITEM 6	Exhibits	19

PART I – FINANCIAL INFORMATION

This Quarterly Report includes forward-looking statements within the meaning of the Securities Exchange Act of 1934 (the “Exchange Act”). These statements are based on management’s beliefs and assumptions, and on information currently available to management. Forward-looking statements include the information concerning our possible or assumed future results of operations set forth under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations.” Forward-looking statements also include statements in which words such as “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “consider” or similar expressions are used.

Forward-looking statements are not guarantees of future performance. They involve risks, uncertainties and assumptions. Our future results and shareholder values may differ materially from those expressed in these forward-looking statements. Readers are cautioned not to put undue reliance on any forward-looking statements.

Item 1.      Financial Statements

America Great Health and Subsidiaries (fka “ Crown Marketing”)

Condensed Consolidated Balance Sheets

	March 31,			June 30,
	2021			2020
	(Unaudited)
ASSETS
CURRENT ASSETS
Cash	$	25,253		$	166
Inventory		1,743			1,141
Other receivable		9,352			2,587
TOTAL CURRENT ASSETS		36,348			3,894
Right-of-use asset		139,205			-
TOTAL ASSETS	$	175,553		$	3,894
LIABILITIES AND SHAREHOLDERS' DEFICIT
CURRENT LIABILITIES
Accounts payable and accrued expense	$	42,019		$	49,273
Income tax payable		800			1,600
Due to related party		290,140			168,028
Lease liability		50,044			-
TOTAL CURRENT LIABILITIES		383,003			218,901
Lease liability - non current		89,161			-
TOTAL LIABILITIES		472,164			218,901
SHAREHOLDERS' DEFICIT
Redeemable, convertible preferred stock, 10,000,000 shares authorized; Series A voting preferred stock, zero shares issued and outstanding		-			-
Common stock, no par value, unlimited shares authorized; 20,363,604,494 and 20,236,021,836 shares issued and outstanding		-			-
Additional paid-in capital		16,445,972			3,071,635
Accumulated deficit		(16,742,583	)		(3,286,642	)
TOTAL SHAREHOLDERS' EQUITY(DEFICIT)		(296,611	)		(215,007	)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$	175,553		$	3,894

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

America Great Health and Subsidiaries (fka “ Crown Marketing”)

Condensed Consolidated Statements of Operations

	Three Months Ended March 31,						Nine Months Ended March 31,
	2021			2020			2021			2020
	(Unaudited)						(Unaudited)
Sales	$	195,535		$	-		$	195,671		$	-
Cost of goods sold		143,905			-			144,049			-
Gross profit		51,630			-			51,622			-
Selling, general and administrative expenses
Professional fee		13,417,971			1,384			13,437,600			6,897
Other		48,503			98			64,688			6,724
		13,466,474			1,482			13,502,288			13,621
Loss from operations		(13,414,844	)		(1,482	)		(13,450,666	)		(13,621	)
Other income (expenses)
Interest expense		(2,157	)		(1,259	)		(5,275	)		(3,631	)
		(2,157	)		(1,259	)		(5,275	)		(3,631	)
Loss before income taxes		(13,417,001	)		(2,741	)		(13,455,941	)		(17,252	)
Income tax provision		-			-			-			800
NET LOSS	$	(13,417,001	)	$	(2,741	)	$	(13,455,941	)	$	(18,052	)
BASIC AND DILUTED LOSS PER SHARE	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED		20,292,390,328			20,236,021,836			20,254,537,034			20,236,021,836

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

America Great Health and Subsidiaries (fka “ Crown Marketing”)

Consolidated Statement of Shareholders' Deficit

	Common Stock				Additional		Accumulated
	Shares		Amount		Paid-in Capital		Deficit			Total
Balance, June 30, 2019		20,236,021,836	$	-	$	3,066,724	$	(3,234,726	)	$	(168,002	)
Imputed interest		-		-		2,372					2,372
Net loss		-		-		-		(15,311	)		(15,311	)
Balance, December 31, 2019(Unaudited)		20,236,021,836		-		3,069,096		(3,250,037	)		(180,941	)
Imputed interest		-		-		1,259		-			1,259
Net loss		-		-		-		(2,741	)		(2,741	)
Balance, March 31, 2020(Unaudited)		20,236,021,836	$	-	$	6,138,192	$	(6,500,074	)	$	(361,882	)
Balance, June 30, 2020		20,236,021,836	$	-	$	3,071,635	$	(3,286,642	)	$	(215,007	)
Imputed interest		-		-		3,118		-			3,118
Net loss		-		-		-		(38,939	)		(38,939	)
Balance, December 31, 2020(Unaudited)		20,236,021,836		-		3,074,753		(3,325,582	)		(250,829	)
Issuance of common stock for compensation		127,582,658		-		13,369,062		-			13,369,062
Imputed interest		-		-		2,157		-			2,157
Net loss		-		-		-		(13,417,001	)		(13,417,001	)
Balance, March 31, 2021(Unaudited)		20,363,604,494	$	-	$	16,445,972	$	(16,742,583	)	$	(296,611	)

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

America Great Health and Subsidiaries (fka “ Crown Marketing”)

Condensed Consolidated Statements of Cash Flows

	Nine Months Ended March 31
	2021			2020
	(Unaudited)
Cash Flows from Operating Activities
Net loss	$	(13,455,941	)	$	(18,052	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation		13,369,062			-
Imputed interest		5,275			3,578
Changes in operating Assets and Liabilities:
Other receivable		(6,765	)		-
Inventory		(602	)		-
Accounts payable and accrued expense		(7,254	)		(3,434	)
Income tax payable		(800	)		800
Net cash used in operating activities		(97,025	)		(17,108	)
Cash Flows from Investing Activities		-			-
Cash Flows from Financing Activities
Advances from related party		201,660			94,106
Repayment to related party		(79,548	)		(77,016	)
Net cash provided by financing activities		122,112			17,090
Net increase (decrease) in cash		25,087			(18	)
Cash beginning of period		166			102
Cash end of period	$	25,253		$	84
Interest paid	$	-		$	-
Taxes paid	$	-		$	-

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

AMERICA GREAT HEALTH AND SUBSIDIARIES

FORMERLY CROWN MARKETING AND SUBSIDIARIES

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

NOTE 1 – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements of America Great Health, formerly Crown Marketing and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the nine months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending June 30, 2021.

Nature of the Business

Through December 31, 2016, the Company’s primary business activity was the sale of various consumer products and accessories. A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang.  In connection with the change of control, the Company sold to its former majority shareholder one of its subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.

On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.

On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.

On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China.

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence.

On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s quarterly report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership.

Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has incurred recurring net losses. For the nine months ended March 31, 2021, the Company recorded a net loss of $13,455,941, used cash to fund operating activities of $97,025, and at March 31, 2021, had a shareholders’ deficit of $296,611. These factors create substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the date these financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

7

During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations.

Our cash needs for the nine months ended March 31, 2021 were primarily met by loans and advances from current majority shareholder.  As of March 31, 2021, we had a cash balance of $25,253. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Basis of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its current wholly owned subsidiary, America Great Health in California. Intercompany transactions and accounts have been eliminated in consolidation.

Estimates 

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services. Actual results could differ from those estimates.

Fair Value Measurements

Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s assumptions.

The Company is required to use observable market data if available without undue cost and effort.

The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.

Loss per Share

Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the nine months ended March 31, 2021 and 2020, as there are no potential shares outstanding that would have a dilutive effect.

8

Income Taxes

Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of March 31, 2021 and June 30, 2020.

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.

Recent Accounting Pronouncements

In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements. 

NOTE 3 – RELATED PARTY TRANSACTIONS

During the nine months ended March 31, 2021, the Company's current majority shareholder advanced $201,660 to the Company as working capital and the Company repaid $79,548 to the shareholder. As of March 31, 2021 and June 30, 2020, the Company owed its current majority shareholder of $290,140 and $168,028 respectively. The advances are non-interest bearing and are due on demand.

Currently the Company is using a premises for free, the premises is leased by a company owned by its current majority shareholder.

NOTE 4 – CONVERTIBLE, REDEEMABLE PREFERRED STOCK

During the year ended June 30, 2016, the Company’s Board of Directors authorized the creation of a series of preferred stock consisting of 1,000,000 shares designated as Series A Preferred Stock (the “Series A”). The Series A is entitled to a dividend of 4%, when and as declared, and is entitled to a liquidation preference of $1 per share plus unpaid dividends. The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days.

The Series A is also subject to adjustments to the Conversion Rate. If the common stock issuable on conversion of the Series A is changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the holders of the Series A shall, upon its conversion, be entitled to receive, in lieu of the common stock which the holders would have become entitled to receive but for such change, a number of shares of such other class or classes of stock that would have been subject to receipt by the holders if they had exercised their rights of conversion of the Series A immediately before that change.

9

In August 2016, the Company filed an amendment to its Articles of Incorporation to increase the number of authorized shares of Series A Preferred Stock from 1,000,000 to 10,000,000.

There were no preferred shares outstanding as of March 31, 2021 and June 30, 2020.

NOTE 5 – SHAREHOLDERS’ DEFICIT

At March 31, 2021 and June 30, 2020, the Company had 20,363,604,494 and 20,236,021,836 shares issued and outstanding, respectively.

On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares was recorded at grant date fair market value at $0.06 per share.

On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares was recorded at grant date fair market value at $0.132 per share.

NOTE 6 – JOINT VENTURE

On March 5th, 2018, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Sino-foreign Co-operative Joint Venture Contract (the “JV Agreement”) with Guangzhou Bona Biotechnology Co., Ltd. (“Bona”) pursuant to which the parties will establish a joint venture (the “JV Company”) for the purpose of promoting and developing sales channels for health and cosmetics related products supplied by AAGH California in the mainland of the People’s Republic of China, the Hong Kong Special Administration Region and the Macau Special Administration Region (together, the “China Market”).

Pursuant to the JV Agreement, AAGH California and Bona will each own 49% and 51% of the JV Company, respectively, and AAGH California has the veto right to the majority shareholder’s decision. The equity method has been used for this JV for the three months ended September 30, 2018. AAGH California will contribute the initial products supply in equivalent of cash amount of RMB 2.45 million to the JV Company and Bona will contribute any required operating capitals, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of the JV Company. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for the JV Company.

The following table summarizes the income statement of Pomeikang.

	From date of equity investment to 12/31/2018
Sales	$	20,740
Gross profit		13,739
Net loss		(2,803	)
49% share		(1,373	)

The following table provides the summary of balance sheet information for Pomeikang.

	As of December 31, 2018
Total assets	$	20,565
Net assets		20,565
49% ownership		10,077
Ending balance of investment account before written off		12,012
Difference		(1,932	)

The difference of $1,932 was mainly due to the effect of exchange rate.

There was no operation during the period from October 1, 2018 to December 31, 2018, therefore at December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. As a result, a loss on disposal of investment of $12,012 was recorded at December 31, 2018. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1.

10

NOTE 7 – INCOME TAXES

As of March 31, 2021, the Company had federal and California income tax net operating loss carryforwards of approximately $16.7 million. These net operating losses will begin to expire 20 years from the date the tax returns are filed.

Uncertain Tax Positions

Interest associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative expenses in the statements of operations. For the nine months ended March 31, 2021 and 2020, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

NOTE 8 – LEASE

The Company has entered into a operating leases agreement with GKT, Alhambra, LP. The lease term of the office space is from December 1, 2020 to November 30, 2023. The current monthly rent including monthly management fee is $4,655.64. The operating lease is listed as separate line item on the Company’s condensed consolidated financial statements and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as a separate line item on the Company’s condensed consolidated financial statements.

Operating lease right-of-use assets and liabilities commencing after December 1, 2020 are recognized at commencement date based on the present value of lease payments over the lease term. For the nine months ended March 31, 2021, the Company recognized approximately $18,623 in total lease costs.

Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments.

Information related to the Company’s operating ROU assets and related lease liabilities are as follows:

	Nine Months Ended March 31, 2021
Cash paid for operating lease liabilities	$	18,623
Weighted-average remaining lease term		2.67
Weighted-average discount rate		5	%
Minimum future lease payments	$	139,205

The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending June 30: 

2021	$	12,278
2022		50,672
2023		53,265
2024		22,990
2025		-
Total	$	139,205

NOTE 9 – SUBSEQUENT EVENTS

1) Shares issued for merger & acquisition

Investment in Imedipus Inc.

On January 30, 2020, the Company and Imediplus Inc. (“Imediplus”), a leading medical institution in Taiwan, entered into a Cooperation Agreement, in which the Company agreed to acquire 48% of the equity of Imediplus, as consideration, the Company shall pay $1,000,000 and issue 662,000,000 common shares to Imediplus. As of June 30, 2021, the Company has not completed its financial and legal due diligence and has not consummated the acquisition of Imediplus.

11

On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus.

Investment in Purecell Group

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at market price of $0.14 per share.

On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP.. 

2) Shares issued for stock compensation

On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13  per share. 

On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share. 

On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share. 

On May 18 , 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus. 

On May 26, 2021, the Company issued an aggregate of 2,450,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.15 per share. 

On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.16 per share. 

3) Shares issued for loan as collateral

On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.04 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. 

12

On June 18, 2021, the Company issued an aggregate of 2,950,000 shares to 6 unrelated parties as collateral for loans of $290,000. The loans have an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. 

On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 4, 2021. 

13

Item 2.  Management’s Discussion and Analysis of Financial Condition and Results of Operations.

Forward Looking Statement Notice

Certain statements made in this Quarterly Report on Form 10-Q are “forward-looking statements” (within the meaning of the Private Securities Litigation Reform Act of 1995) regarding the plans and objectives of management for future operations.  Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements of Crown Marketing, (“we”, “us”, “our” or the “Company”) to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. The forward-looking statements included herein are based on current expectations that involve numerous risks and uncertainties. The Company’s plans and objectives are based, in part, on assumptions involving the continued expansion of business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company.  Although the Company believes its assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance the forward-looking statements included in this Quarterly Report will prove to be accurate.  In light of the significant uncertainties inherent in the forward-looking statements included herein, the inclusion of such information should not be regarded as a representation by the Company or any other person that the objectives and plans of the Company will be achieved.

History and Organization

America Great Health, formerly Crown Marketing, is a Wyoming corporation (the “Company”). A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang.  In connection with the change of control, the Company sold to its former majority shareholder a subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.

On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.

On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.

On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China. 

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence.

On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s quarterly report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership.

14

Overview of Business

The Company will focus its business in the health related industry. The Company’s Chairman and president, Mike Wang, is the owner of several health related businesses below with which The Company is evaluating the possibilities of forming several joint ventures. The Company might effectuate the joint ventures using stocks.

1. H&BG. It is a California company in the business of R &D and sale of vitamins and nutritional supplements. It owns more than 20 formulas and engages contract manufacturers to make these products. The company has built up sales records both in the US as well as in China. On January 4, 2018, the Company entered into a Stock Purchase Agreement with H&BG (the “Seller”) to purchase 51% of common shares of the Seller, for $765,000, which consisted of 63,750,000 outstanding shares of the Company’s common stock at $0.012 per share. On April 5, 2018, the Company entered into a Rescission Agreement (the “Rescission Agreement”) with the seller to rescind the transactions set forth in the Stock Purchase Agreement prior to the transaction closing.

2. Pro Health Inc., a Tennessee company organized in 2016. It entered into a Sales Agreement with Provision Healthcare, LLC, a Tennessee limited liability company, in the selling of ProNova Equipment, which is a Proton Treatment device used in the treatment of cancer. Other than the sale of equipment, Pro Health will also be providing Total Solution Services related with the use of the Equipment.

3. Sales Agreement between Mike Wang and Dr. William Fang for the marketing and sales of Dr. Fang’s early detection system of Cardio Vascular diseases. The device provides unique 3D imaging for the Cardio Vascular conditions for patients and has already won approval of US FDA. It has very positive significance in helping preventing heart attacks, which are the number one killer in the US as well as in the world.

On March 5, 2018, America Great Health, a California Corporation (“AAGH CA”), a wholly owned subsidiary of the Company, entered into a Sino-foreign Co-operative Joint Venture Contract (the “JV Agreement”) with Guangzhou Bona Biotechnology Co., Ltd. (“Bona”) to establish a JV,Pomeikang Biotechnology (Guangzhou) Co., Ltd. (“Pomeikang”), to promote and develop sales channels for health and cosmetics related products supplied by AAGH CA in the mainland of the People’s Republic of China, the Hong Kong Special Administration Region and the Macau Special Administration Region (together, the “China Market”).

Pursuant to the JV Agreement, AAGH CA and Bona each own 49% and 51% of Pomeikang, respectively, and AAGH California has the veto right to stop the majority shareholder’s decision. AAGH CA will contribute the initial products supply in equivalent of cash amount of RMB 2.45 million ($368,000) to Pomeikang and Bona will contribute any required operating capital, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of Pomeikang. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for Pomeikang.

At December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1.

On May 21, 2018, the Company, entered into an Exclusive Oversea Distribution Agreement (the “Agreement”) with Foshan Wanshunbao Technology Co., Ltd. (“Wanshunbao”), a mainland China based company. According to the Agreement, Wanshunbao wishes to promote and develop overseas sales channels for its unique “Mysteries Fruit” tea and related products worldwide. The Company is appointed as Wanshunbao’s exclusive distributor to market and sell the “Mysteries Fruit” herbal tea and related products in geographic areas covers all over the world except mainland China.

In the past 20 years, Wangshunbao has dedicated to improve its R&D, and production of the unique “Mysteries Fruit” and related supplemental products, currently, Wangshunbao has developed a leading role in this industry, and is in the process of expanding its business model worldwide to a 10 billion RMB ($1.5 billion) industry chain. To achieve that goal, Wangshunbao’s management team had been actively seeking a qualified international distributor and business partner to execute its expansion plan.

The Company’s management team was invited to Foshan, China in early May, 2018 to visit Wangshunbao and its production facilities, upon extensive discussion and negotiation, the Company was granted with exclusive distribution rights worldwide for “Mysteries Fruit” tea and related products. The Company believes by introducing “Mysteries Fruit” products to oversee consumers would have a huge beneficial effect; and the management is confident about this business opportunity, as the Company’s core team members all have been in health and supplemental related industry for over 20 years, and has substantial nutrient products sales experiences and marketing channels. The Company is currently conducting preliminary sales campaigns for “Mysteries Fruit” products.

15

The company and Blue Sea International Holdings Co., Ltd. signed a letter of intent on August 28, 2018. According to the letter of intent, Blue Sea International Holdings Co., Ltd. Intends to invest $50 million for the Company's marketing, product development, and merger and acquisition activities. The two parties also signed a marketing contract for 10,000 cardio vascular device after the Company obtains the necessary permit in China.

HuaHengJian (Beijing) Biotechnology Co., Ltd., Zhengzhou RuiBoSi Medical Devices Co., Ltd. and other companies have agreed to sell or lease more than 10,000 cardio vascular device in China after the Company obtains the necessary permit in China.

On January 30, 2020, the Company and Imediplus Inc. (“Imediplus”), a leading medical institution in Taiwan, entered into a Cooperation Agreement, in which the Company agreed to acquire 48% of the equity of Imediplus, as consideration, the Company shall pay $1,000,000 and issue 662,000,000 common shares to Imediplus. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members.

As of June 30, 2021, the Company has not completed its financial and legal due diligence and has not consummated the acquisition of Imediplus.

On April 6, 2021, the Company issued 70,000,000 shares to a shareholder of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus.

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at a price of $0.14 per share.

On May 11, 2021, Aussie Produce PTY LTD ("AP") signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP. 

The company is negotiating an acquisition intention with Hongkong Pure Aesthetics Biotechnology Limited, which holds several patents in stem cell. The patents are valued at nearly $59 million.

The Company is discussing the possibility of establishing a joint venture in California with an individual who has nearly ten years experiences in health products market.

The Company is also planning to conduct additional acquisitions. Mike Wang has approached several health related companies in China and met the management of potential acquisition targets. Rapid economic advances in China in the last thirty years have greatly improved the living standards in China. This in turn brings demand in healthcare products and services. The Company feels strongly that despite the challenges of cross border business, it might be able to acquire some good growth companies and bring good values to our stockholders.

As inherent with any new business development, there are risks involved in such endeavor. For all the healthcare related businesses afore-mentioned, the Company is evaluating what kind of risks we are facing. The Company notices that vitamin and nutrition supplement business is a highly competitive market and faces multiple regulatory monitoring. The compliance challenge is constant. Regarding proton treatment sales, the device is very expensive and for such large ticket item, the procurement process can be long and arduous. The sale of cardio vascular device also has its challenges. The device is not well known and the acceptance of the use requires major efforts in educating not only the medical professionals but also consumers. This would demand financial as well as other resources. Although the Company is making some progress in the Merger and Acquisition efforts, any potential results, if any, are still not certain.

16

Critical Accounting Policies and Estimates

Estimates

The preparation of these consolidated financial statements in accordance with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the dates of the consolidated financial statements and the reported amounts of net sales and expenses during the reported periods.  Actual results may differ from those estimates and such differences may be material to the financial statements.  The more significant estimates and assumptions by management include among others, the fair value of shares of common stock issued for services. The current economic environment has increased the degree of uncertainty inherent in these estimates and assumptions.

Recent Accounting Pronouncements

See Footnote 2 of the financial statements for a discussion of recently issued accounting standards.

Results of Operations

Results of Operations for the three and nine months ended March 31, 2021 compared to the three and nine months ended March 31, 2020.

Sales amounted $195,535 and $0 for the three months ended March 31, 2021 and 2020, respectively. Sales amounted $195,671 and $0 for the nine months ended March 31, 2021 and 2020, respectively. The increase is of sales is because the company sold products to a customer in the three months ended Mach 31, 2021. The products are purchased from the market.

Cost of goods sold amounted $143,905 and $0 for the three months ended March 31, 2021 and 2020, respectively. Cost of goods sold amounted $144,049 and $0 for the nine months ended March 31, 2021 and 2020, respectively. The increase of cost of goods sold is due to increased sales.

Gross profit amounted $51,630 and $0 for the three months ended March 31, 2021 and 2020, respectively. Gross profit amounted $51,622 and $0 for the nine months ended March 31, 2021 and 2020, respectively. The increase of gross profit is due to increased sales.

Operating expenses incurred for the three months ended March 31, 2021 and 2020 was $13,466,474 and $1,482, respectively. Operating expenses incurred for the nine months ended March 31, 2020 and 2019 was $13,502,288 and $13,621, respectively. The increase was mainly due to increased stock compensation of $13,369,062.

Our net loss for the three months ended March 31, 2021 and 2020 was $13,417,001 and $2,741, respectively. Our net loss for the nine months ended March 31, 2021 and 2020 was $13,455,941 and $18,052, respectively. The increase in net loss was mainly due to increased stock compensation of $13,369,062.

Liquidity and Capital Resources

Liquidity is the ability of a company to generate funds to support its current and future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures.

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying consolidated financial statements, the Company has incurred recurring net losses. For the nine months ended March 31, 2020, the Company recorded a net loss of $18,052, used cash to fund operating activities of $17,108, and cash provided by financing activities of $17,090. For the nine months ended March 31, 2021, the Company recorded a net loss of $13,417,001, used cash to fund operating activities of $97,025, and cash provided by financing activities of $122,112. These factors create substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

17

The management’s plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations.

Our cash needs for the nine months ended March 31, 2021 were primarily met by loans and advances from current majority shareholder.  As of March 31, 2021, we had a cash balance of $25,253.  Our new majority shareholders will need to provide all of our working capitals going forward.

Primarily as a result of our recurring losses and our lack of liquidity, we received a report from our independent registered public accounting firm for our financial statements for the year ended June 30, 2020 that includes an explanatory paragraph describing the uncertainty as to our ability to continue as a going concern.

Financial Position

As of March 31, 2021, we had $25,253 in cash, negative working capital of $346,654 and an accumulated deficit of $16,742,583.

Contractual Obligations and Off-Balance Sheet Arrangements

We do not have any contractual obligations or off balance sheet arrangements.

Item 3.  Quantitative and Qualitative Disclosures About Market Risk.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Item 4.  Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Evaluation of Disclosure Controls and Procedures

Based upon an evaluation of the effectiveness of our disclosure controls and procedures performed by our Chief Executive Officer as of the end of the period covered by this report, our Chief Executive Officer concluded that our disclosure controls and procedures were not effective as a result of a weakness in the design of internal control over financial reporting identified below.

As used herein, “disclosure controls and procedures” mean controls and other procedures of our company that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Securities Exchange Act is accumulated and communicated to our management, including our principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Controls

There have been no changes in our internal controls over financial reporting during the period ended March 31, 2021 that have materially affected or are reasonably likely to materially affect our internal controls.

18

PART II — OTHER INFORMATION

Item 1.  Legal Proceedings.

We are not a party to or otherwise involved in any legal proceedings.

In the ordinary course of business, we are from time to time involved in various pending or threatened legal actions.  The litigation process is inherently uncertain and it is possible that the resolution of such matters might have a material adverse effect upon our financial condition and/or results of operations.  However, in the opinion of our management, other than as set forth herein, matters currently pending or threatened against us are not expected to have a material adverse effect on our financial position or results of operations.

Item 1A.  Risk Factors.

As a “smaller reporting company” as defined by Item 10 of Regulation S-K, the Company is not required to provide information required by this Item.

Item 2.  Unregistered Sales of Equity Securities and Use of Proceeds.

Not applicable.

Item 3.  Defaults Upon Senior Securities.

There have been no events which are required to be reported under this Item.

Item 4.  Mine Safety Disclosures.

Not applicable.

Item 5.  Other Information.

None.

Item 6.  Exhibits and Financial Statement Schedules

31.1	Certification of CEO and CFO. Filed herewith.
32.1	Certification pursuant to 18 U.S.C. Section 1350 of CEO and CFO. Filed herewith.
101.INS*	XBRL Instance Document
101.SCH*	XBRL Taxonomy Extension Schema Document
101.CAL*	XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF*	XBRL Taxonomy Extension Definition Linkbase Definition
101.PRE*	XBRL Taxonomy Extension Presentation Linkbase Document
101.LAB*	XBRL Taxonomy Extension Label Linkbase Document

*XBRL (Extensible Business Reporting Language) information is furnished and not filed or a part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, is deemed not filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and otherwise is not subject to liability under these sections. In accordance with SEC Release 33-8238, Exhibit 32.1 is furnished and not filed.

19

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	AMERICA GREAT HEALTH
Dated: July 12, 2021	By:	/s/ Mike Wang
		Mike Wang
		President and Chief Financial Officer (chief financial and accounting officer and duly authorized officer)

20

EX-31.1

EXHIBIT 31.1

CERTIFICATION

I, Mike Wang, certify that:

1. I have reviewed this quarterly report on Form 10-Q of America Great Health;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officer(s) and I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: July 12, 2021	By:	/s/ Mike Wang
		Mike Wang
		President and Chief Financial Officer (chief financial and accounting officer and duly authorized officer)

EX-32.1

EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of America Great Health (the “Company”) on Form 10-Q for the period ending March 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mike Wang, President and Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities and Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: July 12, 2021	By:	/s/ Mike Wang
		Mike Wang
		President and Chief Financial Officer (chief financial and accounting officer and duly authorized officer)

XML

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2021	Jul. 11, 2021
Document Information Line Items
Entity Registrant Name	America Great Health
Document Type	10-Q
Current Fiscal Year End Date	--06-30
Entity Common Stock, Shares Outstanding		21,070,866,399
Amendment Flag	false
Entity Central Index Key	0001098009
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Mar. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Interactive Data Current	No

XML

Condensed Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Jun. 30, 2020
CURRENT ASSETS
Cash	$ 25,253	$ 166
Inventory	1,743	1,141
Other receivable	9,352	2,587
TOTAL CURRENT ASSETS	36,348	3,894
Right-of-use asset	139,205	0
TOTAL ASSETS	175,553	3,894
CURRENT LIABILITIES
Accounts payable and accrued expense	42,019	49,273
Income tax payable	800	1,600
Due to related party	290,140	168,028
Lease liability	50,044	0
TOTAL CURRENT LIABILITIES	383,003	218,901
Lease liability - non current	89,161	0
TOTAL LIABILITIES	472,164	218,901
SHAREHOLDERS' DEFICIT
Redeemable, convertible preferred stock, 10,000,000 shares authorized; Series A voting preferred stock, zero shares issued and outstanding	0	0
Common stock, no par value, unlimited shares authorized; 20,363,604,494 and 20,236,021,836 shares issued and outstanding	0	0
Additional paid-in capital	16,445,972	3,071,635
Accumulated deficit	(16,742,583)	(3,286,642)
TOTAL SHAREHOLDERS' EQUITY(DEFICIT)	(296,611)	(215,007)
TOTAL LIABILITIES AND SHAREHOLDERS' DEFICIT	$ 175,553	$ 3,894

XML

Condensed Consolidated Balance Sheets (Parentheticals) - shares	Mar. 31, 2021	Jun. 30, 2020
Statement of Financial Position [Abstract]
Series A voting preferred stock, shares issued	0	0
Series A voting preferred stock, shares outstanding	0	0
Redeemable, convertible preferred stock, shares authorized	10,000,000	10,000,000
Common stock, shares issued	20,363,604,494	20,236,021,836
Common stock, shares outstanding	20,363,604,494	20,236,021,836

XML

Condensed Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
Income Statement [Abstract]
Sales	$ 195,535	$ 0	$ 195,671	$ 0
Cost of goods sold	143,905	0	144,049	0
Gross profit	51,630	0	51,622	0
Selling, general and administrative expenses
Professional fee	13,417,971	1,384	13,437,600	6,897
Other	48,503	98	64,688	6,724
	13,466,474	1,482	13,502,288	13,621
Loss from operations	(13,414,844)	(1,482)	(13,450,666)	(13,621)
Other income (expenses)
Interest expense	(2,157)	(1,259)	(5,275)	(3,631)
	(2,157)	(1,259)	(5,275)	(3,631)
Loss before income taxes	(13,417,001)	(2,741)	(13,455,941)	(17,252)
Income tax provision	0	0	0	800
NET LOSS	$ (13,417,001)	$ (2,741)	$ (13,455,941)	$ (18,052)
BASIC AND DILUTED LOSS PER SHARE (in Dollars per share)	$ 0.00	$ 0.00	$ 0.00	$ 0.00
WEIGHTED-AVERAGE COMMON SHARES OUTSTANDING BASIC AND DILUTED (in Shares)	20,292,390,328	20,236,021,836	20,254,537,034	20,236,021,836

XML

Consolidated Statement of Shareholders' Equity - USD ($)	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Jun. 30, 2019		$ 3,066,724	$ (3,234,726)	$ (168,002)
Balance (in Shares) at Jun. 30, 2019	20,236,021,836
Imputed Interest		2,372		2,372
Net loss			(15,311)	(15,311)
Balance at Dec. 31, 2019		3,069,096	(3,250,037)	(180,941)
Balance (in Shares) at Dec. 31, 2019	20,236,021,836
Balance at Jun. 30, 2019		3,066,724	(3,234,726)	(168,002)
Balance (in Shares) at Jun. 30, 2019	20,236,021,836
Imputed Interest				3,578
Net loss				(18,052)
Balance at Mar. 31, 2020		6,138,192	(6,500,074)	(361,882)
Balance (in Shares) at Mar. 31, 2020	20,236,021,836
Balance at Dec. 31, 2019		3,069,096	(3,250,037)	(180,941)
Balance (in Shares) at Dec. 31, 2019	20,236,021,836
Imputed Interest		1,259		1,259
Net loss			(2,741)	(2,741)
Balance at Mar. 31, 2020		6,138,192	(6,500,074)	(361,882)
Balance (in Shares) at Mar. 31, 2020	20,236,021,836
Balance at Jun. 30, 2020		3,071,635	(3,286,642)	$ (215,007)
Balance (in Shares) at Jun. 30, 2020	20,236,021,836			20,236,021,836
Imputed Interest		3,118		$ 3,118
Net loss			(38,939)	(38,939)
Balance at Dec. 31, 2020		3,074,753	(3,325,582)	(250,829)
Balance (in Shares) at Dec. 31, 2020	20,236,021,836
Balance at Jun. 30, 2020		3,071,635	(3,286,642)	$ (215,007)
Balance (in Shares) at Jun. 30, 2020	20,236,021,836			20,236,021,836
Imputed Interest				$ 5,275
Net loss				(13,455,941)
Balance at Mar. 31, 2021		16,445,972	(16,742,583)	$ (296,611)
Balance (in Shares) at Mar. 31, 2021	20,363,604,494			20,363,604,494
Balance at Dec. 31, 2020		3,074,753	(3,325,582)	$ (250,829)
Balance (in Shares) at Dec. 31, 2020	20,236,021,836
Issuance of common stock for compensation		13,369,062		13,369,062
Issuance of common stock for compensation (in Shares)	127,582,658
Imputed Interest		2,157		2,157
Net loss			(13,417,001)	(13,417,001)
Balance at Mar. 31, 2021		$ 16,445,972	$ (16,742,583)	$ (296,611)
Balance (in Shares) at Mar. 31, 2021	20,363,604,494			20,363,604,494

XML

Condensed Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Cash Flows from Operating Activities
Net loss	$ (13,455,941)	$ (18,052)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock compensation	13,369,062	0
Imputed interest	5,275	3,578
Other receivable	(6,765)	0
Inventory	(602)	0
Accounts payable and accrued expense	(7,254)	(3,434)
Income tax payable	(800)	800
Net cash used in operating activities	(97,025)	(17,108)
Cash Flows from Financing Activities
Advances from related party	201,660	94,106
Repayment to related party	(79,548)	(77,016)
Net cash provided by financing activities	122,112	17,090
Net increase (decrease) in cash	25,087	(18)
Cash beginning of period	166	102
Cash end of period	25,253	84
Interest paid	0	0
Taxes paid	$ 0	$ 0

XML

BASIS OF PRESENTATION

9 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

NOTE 1 – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements of America Great Health, formerly Crown Marketing and Subsidiaries (the “Company”) have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X.  Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all normal recurring adjustments considered necessary for a fair presentation have been included. Operating results for the nine months ended March 31, 2021 are not necessarily indicative of the results that may be expected for the year ending June 30, 2021.

Nature of the Business

Through December 31, 2016, the Company’s primary business activity was the sale of various consumer products and accessories. A change of control of the Company was completed on January 19, 2017 from Jay Hooper, the former officer and director of the Company and its former majority shareholder. Control was obtained by the sale of 16,155,746,000 shares of Company common stock from Mr. Hooper to an investor group led by Mike Q. Wang.  In connection with the change of control, the Company sold to its former majority shareholder one of its subsidiary for $100 and another subsidiary in exchange for the cancellation of all payables and accrued expenses. After December 31, 2016, the Company’s operations are determined and structured by the new investor group. As such, the Company accounted for all of its assets, liabilities and results of operations up to January 1, 2017 as discontinued operations.

On March 1, 2017, the Company filed with the Secretary of State of the State of Wyoming an Articles of Amendment to change the corporate name from Crown Marketing to America Great Health.

On March 9, 2017, the Company formed a wholly owned subsidiary, America Great Health, under the laws of the State of California.

On June 24, 2019, the Company registered a wholly owned subsidiary in China, Meizhong Health Industry Development Co., Ltd. The subsidiary is mainly engaged in merger and acquisition, investment and financing, and marketing of medical equipment and health products in China.

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence.

On December 7, 2020, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Cooperation Agreement (the “Agreement”) with Brilliant Healthcare Limited. (“Brilliant”) pursuant to which the parties will establish a joint venture in China (the “JV Company”) for the purpose of promoting and developing stem cell related product’s R&D, production, sales, row material procumbent, mergers and acquisitions, and consulting services. As of the time of filing these financial statements with the Company’s quarterly report, the formation of the JV Company has not been completed. After the formation of the JV company is completed, the Company shall invest USD $4.2 million in the JV Company within the next 24 months for 60% equity ownership of the JV Company, Brilliant shall transfer its patented technology (with estimated value of USD $29.8 million) to the JV Company as its capital contribution, to account for 40% equity ownership.

Going Concern

The accompanying condensed consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company has incurred recurring net losses. For the nine months ended March 31, 2021, the Company recorded a net loss of $13,455,941, used cash to fund operating activities of $97,025, and at March 31, 2021, had a shareholders’ deficit of $296,611. These factors create substantial doubt about the Company’s ability to continue as a going concern within the next twelve months from the date these financial statements are available to be issued. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

During the year ended June 30, 2017, the Company’s former majority shareholder sold his shares to an investor group. The new owners’ plans to continue as a going concern revolve around its ability to achieve profitable operations, as well as raise necessary capital to pay ongoing general and administrative expenses of the Company. The ability of the Company to continue as a going concern is dependent on securing additional sources of capital and the success of the Company’s plan. There is no assurance that the Company will be successful in raising the additional capital or in achieving profitable operations.

Our cash needs for the nine months ended March 31, 2021 were primarily met by loans and advances from current majority shareholder.  As of March 31, 2021, we had a cash balance of $25,253. We intend to finance operating costs over the next twelve months with existing cash on hand and advance from current majority shareholder.

XML

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Significant Accounting Policies [Text Block]

NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Basis of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its current wholly owned subsidiary, America Great Health in California. Intercompany transactions and accounts have been eliminated in consolidation.

Estimates 

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services. Actual results could differ from those estimates.

Fair Value Measurements

Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s assumptions.

The Company is required to use observable market data if available without undue cost and effort.

The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.

Loss per Share

Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the nine months ended March 31, 2021 and 2020, as there are no potential shares outstanding that would have a dilutive effect.

Income Taxes

Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of March 31, 2021 and June 30, 2020.

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.

Recent Accounting Pronouncements

In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements. 

XML

RELATED PARTY TRANSACTIONS

9 Months Ended

Mar. 31, 2021

Related Party Transactions [Abstract]

Related Party Transactions Disclosure [Text Block]

NOTE 3 – RELATED PARTY TRANSACTIONS

During the nine months ended March 31, 2021, the Company's current majority shareholder advanced $201,660 to the Company as working capital and the Company repaid $79,548 to the shareholder. As of March 31, 2021 and June 30, 2020, the Company owed its current majority shareholder of $290,140 and $168,028 respectively. The advances are non-interest bearing and are due on demand.

Currently the Company is using a premises for free, the premises is leased by a company owned by its current majority shareholder.

XML

CONVERTIBLE, REDEEMABLE PREFERRED STOCK

9 Months Ended

Mar. 31, 2021

Disclosure Text Block Supplement [Abstract]

Preferred Stock [Text Block]

NOTE 4 – CONVERTIBLE, REDEEMABLE PREFERRED STOCK

During the year ended June 30, 2016, the Company’s Board of Directors authorized the creation of a series of preferred stock consisting of 1,000,000 shares designated as Series A Preferred Stock (the “Series A”). The Series A is entitled to a dividend of 4%, when and as declared, and is entitled to a liquidation preference of $1 per share plus unpaid dividends. The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”). In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days.

The Series A is also subject to adjustments to the Conversion Rate. If the common stock issuable on conversion of the Series A is changed into the same or a different number of shares of any other class or classes of stock, whether by capital reorganization, reclassification, or otherwise (other than a subdivision or combination of shares provided for above), the holders of the Series A shall, upon its conversion, be entitled to receive, in lieu of the common stock which the holders would have become entitled to receive but for such change, a number of shares of such other class or classes of stock that would have been subject to receipt by the holders if they had exercised their rights of conversion of the Series A immediately before that change.

In August 2016, the Company filed an amendment to its Articles of Incorporation to increase the number of authorized shares of Series A Preferred Stock from 1,000,000 to 10,000,000.

There were no preferred shares outstanding as of March 31, 2021 and June 30, 2020.

XML

SHAREHOLDERS' DEFICIT

9 Months Ended

Mar. 31, 2021

Stockholders' Equity Note [Abstract]

Stockholders' Equity Note Disclosure [Text Block]

NOTE 5 – SHAREHOLDERS’ DEFICIT

At March 31, 2021 and June 30, 2020, the Company had 20,363,604,494 and 20,236,021,836 shares issued and outstanding, respectively.

On January 22, 2021, the Company issued an aggregate of 48,220,124 shares of common stock to 28 unrelated parties as compensation for services. The issuance of these shares was recorded at grant date fair market value at $0.06 per share.

On March 10, 2021, the Company issued an aggregate of 79,362,534 shares of common stock to 54 unrelated parties as compensation for services. The issuance of these shares was recorded at grant date fair market value at $0.132 per share.

XML

JOINT VENTURE

9 Months Ended

Mar. 31, 2021

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments and Joint Ventures Disclosure [Text Block]

NOTE 6 – JOINT VENTURE

On March 5th, 2018, America Great Health, a California Corporation (“AAGH California”), a wholly owned subsidiary of the Company, entered into a Sino-foreign Co-operative Joint Venture Contract (the “JV Agreement”) with Guangzhou Bona Biotechnology Co., Ltd. (“Bona”) pursuant to which the parties will establish a joint venture (the “JV Company”) for the purpose of promoting and developing sales channels for health and cosmetics related products supplied by AAGH California in the mainland of the People’s Republic of China, the Hong Kong Special Administration Region and the Macau Special Administration Region (together, the “China Market”).

Pursuant to the JV Agreement, AAGH California and Bona will each own 49% and 51% of the JV Company, respectively, and AAGH California has the veto right to the majority shareholder’s decision. The equity method has been used for this JV for the three months ended September 30, 2018. AAGH California will contribute the initial products supply in equivalent of cash amount of RMB 2.45 million to the JV Company and Bona will contribute any required operating capitals, experienced sales team, promotional effort, and customer services to ensure normal day to day operation of the JV Company. Bona will also be responsible for acquiring any required government permits, sales permits, and business licenses for the JV Company.

The following table summarizes the income statement of Pomeikang.

	From date of equity investment to 12/31/2018
Sales	$	20,740
Gross profit		13,739
Net loss		(2,803	)
49% share		(1,373	)

The following table provides the summary of balance sheet information for Pomeikang.

	As of December 31, 2018
Total assets	$	20,565
Net assets		20,565
49% ownership		10,077
Ending balance of investment account before written off		12,012
Difference		(1,932	)

The difference of $1,932 was mainly due to the effect of exchange rate.

There was no operation during the period from October 1, 2018 to December 31, 2018, therefore at December 31, 2018, the Company decided to no longer participate in Pomeikang’s operations. As a result, a loss on disposal of investment of $12,012 was recorded at December 31, 2018. On April 1, 2019, AAGH California transferred its 49% ownership to Bona for $1.

XML

INCOME TAXES

9 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

NOTE 7 – INCOME TAXES

As of March 31, 2021, the Company had federal and California income tax net operating loss carryforwards of approximately $16.7 million. These net operating losses will begin to expire 20 years from the date the tax returns are filed.

Uncertain Tax Positions

Interest associated with unrecognized tax benefits are classified as income tax, and penalties are classified in selling, general and administrative expenses in the statements of operations. For the nine months ended March 31, 2021 and 2020, the Company had no unrecognized tax benefits and related interest and penalties expenses. Currently, the Company is not subject to examination by major tax jurisdictions.

XML

LEASE

9 Months Ended

Mar. 31, 2021

Disclosure Text Block [Abstract]

Lessee, Operating Leases [Text Block]

NOTE 8 – LEASE

The Company has entered into a operating leases agreement with GKT, Alhambra, LP. The lease term of the office space is from December 1, 2020 to November 30, 2023. The current monthly rent including monthly management fee is $4,655.64. The operating lease is listed as separate line item on the Company’s condensed consolidated financial statements and represent the Company’s right to use the underlying asset for the lease term. The Company’s obligation to make lease payments are also listed as a separate line item on the Company’s condensed consolidated financial statements.

Operating lease right-of-use assets and liabilities commencing after December 1, 2020 are recognized at commencement date based on the present value of lease payments over the lease term. For the nine months ended March 31, 2021, the Company recognized approximately $18,623 in total lease costs.

Because the rate implicit in each lease is not readily determinable, the Company uses its incremental borrowing rate to determine the present value of the lease payments.

Information related to the Company’s operating ROU assets and related lease liabilities are as follows:

	Nine Months Ended March 31, 2021
Cash paid for operating lease liabilities	$	18,623
Weighted-average remaining lease term		2.67
Weighted-average discount rate		5	%
Minimum future lease payments	$	139,205

The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending June 30: 

2021	$	12,278
2022		50,672
2023		53,265
2024		22,990
2025		-
Total	$	139,205

XML

SUBSEQUENT EVENTS

9 Months Ended

Mar. 31, 2021

Subsequent Events [Abstract]

Subsequent Events [Text Block]

NOTE 9 – SUBSEQUENT EVENTS

1) Shares issued for merger & acquisition

Investment in Imedipus Inc.

On January 30, 2020, the Company and Imediplus Inc. (“Imediplus”), a leading medical institution in Taiwan, entered into a Cooperation Agreement, in which the Company agreed to acquire 48% of the equity of Imediplus, as consideration, the Company shall pay $1,000,000 and issue 662,000,000 common shares to Imediplus. As of June 30, 2021, the Company has not completed its financial and legal due diligence and has not consummated the acquisition of Imediplus.

On April 6, 2021, the Company issued 70,000,000 shares to a director of Imediplus as collateral in exchange for getting trust of 2,500,000 shares that is 5% of Imediplus.

Investment in Purecell Group

On June 30, 2020, the Company and Purecell Group (“Purecell”), a leading anti-aging medical institution in Australia, entered into a Cooperation Agreement, in which the Company agreed to acquire 51% of the equity of Purecell, as consideration, the Company shall issue 510,000,000 common shares to Purecell’s nominated trustee. Upon completion of the acquisition transaction, Purecell shall remain autonomy in its day to day operation, including recruiting and retaining management team members. On February 10, 2021, the Company completed its financial and legal due diligence. On April 6, 2021, the Company issued 510,000,000 shares to two shareholders of Purecell Group PTY Ltd ("Purecell" ) in exchange of 51% of ownership of Purecell. On April 6, 2021, the Company issued 50,000,000 shares of common stock to Purecell’s project introducer as compensation for services, at market price of $0.14 per share.

On May 11, 2021, Aussie Produce PTY LTD (“AP”) signed agreement with Purecell to invest $2,340,000 in exchange of 6% of total outstanding shares of Purecell and 35,000,000 shares of the Company owned by Purecell. Purecell will issue 6% shares to AP in exchange for the $2,340,000 investment. In addition, Purecell will issue 68,372 shares to AP and issue 71,163 shares to the Company. The Company will also issue additional 31,212,000 shares to Purecell. Purecell will use the proceeds to acquire VERITA PHARMA, which is a medicine factory. On May 26, 2021, the Company issued 35,000,000 shares to shareholder of AP.. 

2) Shares issued for stock compensation

On April 7, 2021, the Company issued an aggregate of 6,621,905 shares of common stock to 12 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.13  per share. 

On May 5, 2021, the Company issued an aggregate of 1,300,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share. 

On May 18, 2021, the Company issued an aggregate of 7,140,000 shares of common stock to 5 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.14 per share. 

On May 18 , 2021, the Company and David Tsai (“Dr. Tsai”), a pioneer in anti-cancer peptide research and invention in the United States, entered into a Cooperation Agreement, in which Dr. Tsai shall provide to the Company of relevant theories, technologies, methods, sources of raw materials, processing and production techniques, quality standards, quality control methods and other information and details related to his anti-cancer protein peptides, oral insulin and activation technology; Dr. Tsai shall also be responsible for the whole process of technology and product production, application and implementation, as well as professional technical support, consultation and cooperation in the process of product verification, publicity, promotion and sales. As consideration, the Company agreed to grant 8 million shares of AAGH common stock to Dr. Tsai along with certain monthly compensations and sales bonus. 

On May 26, 2021, the Company issued an aggregate of 2,450,000 shares of common stock to 6 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.15 per share. 

On June 18, 2021, the Company issued an aggregate of 11,300,000 shares of common stock to 22 unrelated parties as compensation for services. The issuance of these shares is recorded at grant date fair market value at $0.16 per share. 

3) Shares issued for loan as collateral

On May 5, 2021, the Company issued 10,000,000 shares to an unrelated party as collateral for a loan of $200,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.04 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on April 27, 2021. 

On June 18, 2021, the Company issued an aggregate of 2,950,000 shares to 6 unrelated parties as collateral for loans of $290,000. The loans have an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 3, 2021. 

On June 18, 2021, the Company issued 500,000 shares to an unrelated party as collateral for a loan of $50,000. The loan has an annual interest rate of 20%. The principle and interest are due in five years. The shares issued are restricted and will be returned to the Company after the principle and interest are paid in full. If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven. The Company received the proceed on June 4, 2021. 

XML

Accounting Policies, by Policy (Policies)

9 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Basis of Presentation

The accompanying CFS were prepared in conformity with accounting principles generally accepted in the United States of America (“US GAAP”).

Consolidation, Policy [Policy Text Block]

Basis of Consolidation

The condensed consolidated financial statements include the accounts of the Company and its current wholly owned subsidiary, America Great Health in California. Intercompany transactions and accounts have been eliminated in consolidation.

Use of Estimates, Policy [Policy Text Block]

Estimates 

The preparation of the financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Significant estimates include accounting for potential liabilities and the assumptions made in valuing stock instruments issued for services. Actual results could differ from those estimates

Fair Value Measurement, Policy [Policy Text Block]

Fair Value Measurements

Fair value measurements are determined using authoritative guidance issued by the FASB, with the exception of the application of the guidance to non-recurring, non-financial assets and liabilities as permitted. Fair value is defined in the authoritative guidance as the price that would be received to sell an asset or paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. A fair value hierarchy was established, which prioritizes the inputs used in measuring fair value into three broad levels as follows:

Level 1—Quoted prices in active markets for identical assets or liabilities.

Level 2—Inputs, other than the quoted prices in active markets, are observable either directly or indirectly.

Level 3—Unobservable inputs based on the Company’s assumptions.

The Company is required to use observable market data if available without undue cost and effort.

The Company’s financial instruments include cash and accounts payable. Management has estimated that the carrying amounts approximate their fair value due to the short-term nature.

Earnings Per Share, Policy [Policy Text Block]

Loss per Share

Basic earnings (loss) per share are computed by dividing income available to common shareholders by the weighted-average number of common shares available. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The Company’s diluted loss per share is the same as the basic loss per share for the nine months ended March 31, 2021 and 2020, as there are no potential shares outstanding that would have a dilutive effect.

Income Tax, Policy [Policy Text Block]

Income Taxes

Income tax expense is based on pretax financial accounting income. Deferred tax assets and liabilities are recognized for the expected tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts. Valuation allowances are recorded to reduce deferred tax assets to the amount that will more likely than not be realized. The Company recorded a valuation allowance against its deferred tax assets as of March 31, 2021 and June 30, 2020.

The Company accounts for uncertainty in income taxes using a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon settlement. The Company classifies the liability for unrecognized tax benefits as current to the extent that the Company anticipates payment (or receipt) of cash within one year. Interest and penalties related to uncertain tax positions are recognized in the provision for income taxes.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements

In July 2017, the FASB issued Accounting Standards Update 2017-11, “Earnings Per Share (Topic 260); Distinguishing Liabilities from Equity (Topic 480); Derivatives and Hedging (Topic 815): (Part I) Accounting for Certain Financial Instruments with Down Round Features, (Part II)”, which is the replacement of the Indefinite Deferral for Mandatorily Redeemable Financial Instruments of Certain Nonpublic Entities and Certain Mandatorily Redeemable Noncontrolling Interests with a Scope Exception. The amendments in Part I of this Update that relate to the recognition, measurement, and earnings per share of certain freestanding equity-classified financial instruments that include down round features affect entities that present earnings per share in accordance with the guidance in Topic 260, Earnings Per Share. The amendments in Part II of this Update do not have an accounting effect. The amendments in Part I of the update are effective for fiscal year, and interim periods within those fiscal years, beginning after December 15, 2018. The Company is assessing the impact to its accounting practices and financial reporting procedures as a result of the issuance of this standard.

Other recent accounting pronouncements issued by the FASB, including its Emerging Issues Task Force, the American Institute of Certified Public Accountants, and the Securities and Exchange Commission did not or is not believed by management to have a material impact on the Company’s present or future consolidated financial statements.

XML

JOINT VENTURE (Tables)

9 Months Ended

Mar. 31, 2021

Equity Method Investments and Joint Ventures [Abstract]

Equity Method Investments [Table Text Block]

The following table summarizes the income statement of Pomeikang.

	From date of equity investment to 12/31/2018
Sales	$	20,740
Gross profit		13,739
Net loss		(2,803	)
49% share		(1,373	)

	As of December 31, 2018
Total assets	$	20,565
Net assets		20,565
49% ownership		10,077
Ending balance of investment account before written off		12,012
Difference		(1,932	)

XML

LEASE (Tables)

9 Months Ended

Mar. 31, 2021

Disclosure Text Block [Abstract]

Lease, Cost [Table Text Block]

Information related to the Company’s operating ROU assets and related lease liabilities are as follows:

	Nine Months Ended March 31, 2021
Cash paid for operating lease liabilities	$	18,623
Weighted-average remaining lease term		2.67
Weighted-average discount rate		5	%
Minimum future lease payments	$	139,205

Lessee, Operating Lease, Liability, Maturity [Table Text Block]

The following table presents the amortization of the Company’s lease liabilities under ASC 842 for each of the following years ending June 30:

2021	$	12,278
2022		50,672
2023		53,265
2024		22,990
2025		-
Total	$	139,205

XML

BASIS OF PRESENTATION (Details) ¥ in Thousands				3 Months Ended		6 Months Ended		9 Months Ended		12 Months Ended
	Dec. 07, 2020 USD ($)	Jun. 30, 2020 USD ($) shares	Jan. 19, 2017 USD ($) shares	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Dec. 31, 2020 USD ($)	Dec. 31, 2019 USD ($)	Mar. 31, 2021 USD ($)	Mar. 31, 2020 USD ($)	Jun. 30, 2018 CNY (¥)	Jun. 30, 2019 USD ($)	Dec. 31, 2018
BASIS OF PRESENTATION (Details) [Line Items]
Stock Issued During Period, Shares, Acquisitions (in Shares) | shares			16,155,746,000
Proceeds from Sales of Business, Affiliate and Productive Assets			$ 100
Equity Method Investment, Ownership Percentage										49.00%
Payments to Acquire Interest in Joint Venture | ¥										¥ 2,450
Net Income (Loss) Attributable to Parent				$ (13,417,001)	$ (2,741)	$ (38,939)	$ (15,311)	$ (13,455,941)	$ (18,052)
Net Cash Provided by (Used in) Operating Activities								(97,025)	(17,108)
Stockholders' Equity Attributable to Parent		$ (215,007)		(296,611)	$ (361,882)	$ (250,829)	$ (180,941)	(296,611)	$ (361,882)		$ (168,002)
Cash		$ 166		$ 25,253				$ 25,253
Corporate Joint Venture [Member]
BASIS OF PRESENTATION (Details) [Line Items]
Equity Method Investment, Ownership Percentage	60.00%											49.00%
Payments to Acquire Interest in Joint Venture	$ 4,200,000
Noncontrolling Interest in Joint Ventures	$ 29,800,000
Corporate Joint Venture [Member] | Brilliant Healthcare Limited [Member]
BASIS OF PRESENTATION (Details) [Line Items]
Equity Method Investment, Ownership Percentage	40.00%
Purecell Group [Member]
BASIS OF PRESENTATION (Details) [Line Items]
Stock Issued During Period, Shares, Acquisitions (in Shares) | shares		510,000,000
Equity Method Investment, Ownership Percentage		51.00%

XML

RELATED PARTY TRANSACTIONS (Details) - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Related Party Transactions [Abstract]
Proceeds from Related Party Debt	$ 201,660
Repayments of Related Party Debt	79,548	$ 77,016
Due to Related Parties, Current	$ 290,140		$ 168,028

XML

CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) - Series A Preferred Stock [Member] - $ / shares	12 Months Ended
	Jun. 30, 2016	Aug. 31, 2016
CONVERTIBLE, REDEEMABLE PREFERRED STOCK (Details) [Line Items]
Preferred Stock, Shares Authorized	1,000,000	10,000,000
Preferred Stock, Dividend Rate, Percentage	4.00%
Preferred Stock, Liquidation Preference Per Share	$ 1
Preferred Stock, Redemption Terms	The Series A is redeemable at the option of the Company at any time, in whole or in part, at a price of $1.00 per share, plus 4% per annum thereupon from the date of issuance (the “Stated Value”).
Preferred Units, Description	In the event of any liquidation, dissolution or winding up of the Corporation, whether voluntary or involuntary, the Series A shall be entitled to a preferential amount equal to the Stated Value, prior to the holders of common stock receiving any distribution. Each share of Series A is automatically converted on the Conversion Date into a number of shares of common stock of the Company at the initial conversion rate (the “Conversion Rate”), which shall be the Stated Value as of the date of conversion divided by the Market Price. The Market Price for purposes of this Section 5 shall be equal to the average closing sales price of the Common Stock over the 5 previous trading days

XML

SHAREHOLDERS' DEFICIT (Details)	Mar. 10, 2021 $ / shares shares	Jan. 21, 2021 $ / shares shares	Mar. 31, 2021 shares	Jun. 30, 2020 shares
Stockholders' Equity Note [Abstract]
Common Stock, Shares, Outstanding			20,363,604,494	20,236,021,836
Common Stock, Shares, Issued			20,363,604,494	20,236,021,836
Stock Issued During Period, Shares, Issued for Services	79,362,534	48,220,124
Number of shareholders	54	28
Shares Issued, Price Per Share (in Dollars per share) | $ / shares	$ 0.132	$ 0.06

XML

JOINT VENTURE (Details) ¥ in Thousands		12 Months Ended		15 Months Ended
	Apr. 01, 2019 USD ($)	Jun. 30, 2018 USD ($)	Jun. 30, 2018 CNY (¥)	Dec. 31, 2018 USD ($)
JOINT VENTURE (Details) [Line Items]
Equity Method Investment, Ownership Percentage		49.00%	49.00%
Payments to Acquire Interest in Joint Venture | ¥			¥ 2,450
Foreign Currency Transaction Gain (Loss), Realized		$ 1,932
Gain (Loss) on Disposition of Assets				$ (12,012)
Guangzhou Bona Niotechnology Co., Ltd [Member]
JOINT VENTURE (Details) [Line Items]
Equity Method Investment, Ownership Percentage	49.00%
Payments to Acquire Interest in Joint Venture	$ 1
Guangzhou Bona Niotechnology Co., Ltd [Member]
JOINT VENTURE (Details) [Line Items]
Equity Method Investment, Ownership Percentage		51.00%	51.00%

XML

JOINT VENTURE (Details) - Equity Method Investments - Corporate Joint Venture [Member]	6 Months Ended	10 Months Ended
	Dec. 31, 2018 USD ($)	Dec. 31, 2018 USD ($)
Schedule of Equity Method Investments [Line Items]
Sales		$ 20,740
Gross profit		13,739
Net loss		(2,803)
49% share		(1,373)
Total assets	$ 20,565	20,565
Net assets	20,565	20,565
49% ownership	10,077	10,077
Ending balance of investment account before written off	12,012	$ 12,012
Difference	$ (1,932)

XML

JOINT VENTURE (Details) - Equity Method Investments (Parentheticals)	Dec. 07, 2020	Dec. 31, 2018
Corporate Joint Venture [Member]
Schedule of Equity Method Investments [Line Items]
Ownership	60.00%	49.00%

XML

INCOME TAXES (Details) $ in Millions	Mar. 31, 2021 USD ($)
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 16.7

XML

LEASE (Details)	9 Months Ended
	Mar. 31, 2021 USD ($)
LEASE (Details) [Line Items]
Operating Lease, Expense	$ 18,623
Minimum [Member]
LEASE (Details) [Line Items]
Operating Lease, Expense	$ 4,655.64

XML

LEASE (Details) - Lease, Cost	9 Months Ended
	Mar. 31, 2021 USD ($)
Lease, Cost [Abstract]
Cash paid for operating lease liabilities	$ 18,623
Weighted-average remaining lease term	2 years 244 days
Weighted-average discount rate	5.00%
Minimum future lease payments	$ 139,205

XML

LEASE (Details) - Lessee, Operating Lease, Liability, Maturity	Mar. 31, 2021 USD ($)
Lessee, Operating Lease, Liability, Maturity [Abstract]
2021	$ 12,278
2022	50,672
2023	53,265
2024	22,990
2025	0
Total	$ 139,205

XML

SUBSEQUENT EVENTS (Details)	Jun. 18, 2021 USD ($) $ / shares shares	May 26, 2021 $ / shares shares	May 18, 2021 $ / shares shares	May 11, 2021 USD ($) shares	May 05, 2021 USD ($) $ / shares shares	Apr. 07, 2021 $ / shares shares	Apr. 06, 2021 $ / shares shares	Mar. 10, 2021 $ / shares shares	Jan. 21, 2021 $ / shares shares	Jun. 30, 2020 USD ($) shares	Jan. 19, 2017 shares	Jan. 30, 2020	Jun. 30, 2018
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage													49.00%
Stock Issued During Period, Shares, Acquisitions											16,155,746,000
Number of shareholders								54	28
Shares Issued, Price Per Share (in Dollars per share) | $ / shares								$ 0.132	$ 0.06
Stock Issued During Period, Shares, Issued for Services								79,362,534	48,220,124
Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Shares Issued, Price Per Share (in Dollars per share) | $ / shares	$ 0.16	$ 0.15	$ 0.14		$ 0.14	$ 0.13
Stock Issued During Period, Shares, Issued for Services	11,300,000	2,450,000	7,140,000		1,300,000	6,621,905
Number of Unrelated Parties	22	6	5		6	12
Dr. Tsai [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Issued for Services			8,000,000
Imediplus Inc. [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage												48.00%
Payments to Acquire Businesses, Gross (in Dollars) | $										$ 1,000,000
Stock Issued During Period, Shares, Acquisitions										662,000,000
Imediplus Inc. [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage							5.00%
Stock Issued During Period, Shares, Acquisitions							70,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares							2,500,000
Purecell Group [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage										51.00%
Stock Issued During Period, Shares, Acquisitions										510,000,000
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares							510,000,000			510,000,000
Purecell Group [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage							51.00%
Stock Issued During Period, Shares, Acquisitions				31,212,000
Number of shareholders							2
Shares Issued, Shares, Share-based Payment Arrangement, before Forfeiture							50,000,000
Shares Issued, Price Per Share (in Dollars per share) | $ / shares							$ 0.14
Sale of Stock, Number of Shares Issued in Transaction				71,163
Loan #1 [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Other					10,000,000
Debt Instrument, Face Amount (in Dollars) | $					$ 200,000
Debt Instrument, Interest Rate, Stated Percentage					20.00%
Debt Instrument, Term					5 years
Long-term Debt, Maturities, Repayment Terms					If the Company's stock price remains above $0.04 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven.
Loan #2 [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Number of Unrelated Parties	6
Stock Issued During Period, Shares, Other	2,950,000
Debt Instrument, Face Amount (in Dollars) | $	$ 290,000
Debt Instrument, Interest Rate, Stated Percentage	20.00%
Debt Instrument, Term	5 years
Long-term Debt, Maturities, Repayment Terms	If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven.
Loan #3 [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Stock Issued During Period, Shares, Other	500,000
Debt Instrument, Face Amount (in Dollars) | $	$ 50,000
Debt Instrument, Interest Rate, Stated Percentage	20.00%
Debt Instrument, Term	5 years
Long-term Debt, Maturities, Repayment Terms	If the Company's stock price remains above $0.2 continuously over 30 days following the maturity date, the stock will become tradable and the remaining principle and interest of loan will be forgiven.
Aussie Produce PTY LTD [Member] | Purecell Group [Member] | Subsequent Event [Member]
SUBSEQUENT EVENTS (Details) [Line Items]
Equity Method Investment, Ownership Percentage				6.00%
Proceeds from Issuance or Sale of Equity (in Dollars) | $				$ 2,340,000
Stock Issued During Period, Shares, New Issues		35,000,000		35,000,000
Sale of Stock, Number of Shares Issued in Transaction				68,372